Current status of transarterial radioembolization

Table 2 Summary of studies on ⁹⁰Y-transarterial radioembolization in hepatocellular carcinoma with more than 50 patients

Ref.	Patients (n)	Particle type	Stage	Design	Response (%)					Median survival (mo)
					CR	PR	SD	AR	PD
Lau et al[73]	71	Resin	CHILD A/B	Retrospective	0	27	65	92	8	9.4
Carr[74]	65	Glass	Okuda I/II	Prospective	3	28	40	71	29	Okuda I = 21.6; Okuda II = 10
Geschwind et al[75]	80	Glass	CHILD A/B	Retrospective	NA	NA	NA	NA	NA	CHILD A = 18.9; CHILD B = 8.2
Hilgard et al[34]	108	Glass	CHILD A/B	Retrospective	3	37	53	94	6	16.4 (CHILD A = 17.4; CHILD B = 6)
Salem et al[33]	291	Glass	CHILD A/B	Prospective	23	34	NA	NA	NA	CHILD A = 17.2; CHILD B = 7.7
Sangro et al[39]	325	Resin	BCLC A-D	Retrospective						12.8 (BCLC A = 24.4; BCLC B = 16.9; BCLC C = 10)
Mazzaferro et al[35]	52	Glass	CHILD A/B	Prospective	9.6	30.8	38.4	78.8	21.2	15

CR: Complete response; PR: Partial response; SD: Stable disease; AR: Any response; PD: Progressive disease; NA: Not available; BCLC: Barcelona Clinic Liver Cancer.